The COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic. Using the infectious disease expertise of their existing research networks and global partners, NIAID has directed the networks to address the pressing need for vaccines and monoclonal antibodies (mAbs) against SARS-CoV-2.

The CoVPN will receive data for the CoVPN efficacy trials to support various statistical analyses from the various companies and will derive analysis-ready datasets for sharing among the CoVPN statisticians and investigators, NIAID/BARDA.